Mutation Research/Reviews in Mutation Research
ReviewMicronuclei frequency in peripheral blood lymphocytes of cancer patients: A meta-analysis
Introduction
Changes in chromosome structure and number, as well as genomic instability, are major events in the etiological pathway leading to cancer [1], [2]. The use of biomarkers associated with these events may provide useful tools for the early detection of disease-related changes [3]. Markers of chromosome damage such as the frequency of chromosomal aberrations (CA) and micronuclei (MN) are among the most frequently used biomarkers for this purpose [4], [5], [6], [7]. The similarity between the level of chromosome damage in surrogate tissues, such as oral mucosa or peripheral blood lymphocytes (PBL), and the corresponding damage in cancer-prone tissues provide the rationale for the use of these biomarkers as markers of cancer risk [8]. In particular, the high reliability and low cost of the micronucleus assay has contributed to the worldwide success and adoption of this biomarker for in vitro and in vivo studies of genome damage [5]. Indeed, the MN assay has in fact evolved into a “cytome” method for comprehensively measuring chromosome-instability phenotypes and altered cellular viabilities [9]. Micronuclei can be generated through different processes, i.e., chromosome breakage and chromosome loss (aneuploidy) [10], [11], [12] (Fig. 1).
The hypothesis of an association between MN frequency and cancer development is supported by a number of observations. The most substantiated include: (i) the high frequency of this biomarker in untreated cancer patients and in subjects affected by cancer-prone congenital diseases, (ii) the correlation existing between genotoxic MN-inducing agents and carcinogenicity, and (ii) the inverse correlation between MN frequency and the blood concentration and/or dietary intake of certain micronutrients associated with reduced cancer risk [11]. Further evidence comes from the results of recent cohort studies, which in most cases demonstrated that the frequency of CA [8], [13] (given the mechanistic and experimental correlation existing between CA and MN) or MN [11], [14] in PBL of healthy subjects is a predictor of cancer risk. However, despite this extensive evidence, it is difficult to establish a causal relationship between MN frequency and cancer risk because a high MN level in cancer patients could be a consequence of their disease status, i.e., reverse causality, or reflect their individual susceptibility to genomic instability events [14].
The present article aims at evaluating and summarizing the available evidence linking cancer status to MN formation in PBL. The use of the meta-analysis seems the most informative way to extract information from studies on biomarkers when the evidence from single studies is too sparse to support definite conclusions [5], [15]. However, given the heterogeneity of human studies available in the scientific literature, we decided to perform separate meta-analyses, not only to compare MN frequency in untreated cancer patients vs. referent donors, but also to identify the extent of individual susceptibility in cancer patients undergoing radio-therapeutic treatment.
Section snippets
Search strategy
The main purpose of this study was to summarize the evidence published in the literature concerning the association between MN frequency in PBL and the presence of a diagnosis of cancer. To avoid the effect of chemo or radiotherapy, studies on untreated patients were preferentially selected.
We performed an extensive literature search without any language restriction by using the MedLine/PubMed database (National Library of Medicine, National Institutes of Health, Bethesda, MD, USA-//www.ncbi.nlm.nih.gov/PubMed
Results
The main characteristics of original datasets are shown in Table 3, Table 4, Table 5. For each study, we reported selected design features (cancer type, size of the study groups, percentage of males and mean age), main findings (mean MN frequency ± standard error (S.E.) in 1000 binucleated cells), the patient/referent FRs, and the first author and the year of publication. We evaluated the potential confounding effect of selected covariates, i.e., mean age and the percentages of males and smokers
Discussion
The main purpose of this study is to evaluate and summarize the available evidence linking cancer status to MN formation in PBL. The frequency of this biomarker in surrogate tissues as a marker of cancer risk and progression is a topic attracting increasing interest for its potential applications to clinical oncology and public health, as confirmed by the dramatically increasing trend of published papers. The heterogeneity of studies retrieved from the MedLine forced us to extend our interests
Conclusion
The results of this review substantiate the existing evidence about a role of MN in various steps of carcinogenesis and clearly show that the level of baseline chromosome damage in untreated cancer patients is much higher than in cancer-free referents. Indeed, MN are generally used as a biomarker of chromosomal damage, genome instability, and cancer risk, integrating acquired mutations and genetic susceptibility. Several factors could explain cancer predictivity of MN, e.g., environmental
Acknowledgements
We thank Donatella Ugolini (National Cancer Research Institute, Genoa, Italy) for her help in search of the MedLine/PubMed database. This study was supported by grants funded by the Associazione Italiana per la Ricerca sul Cancro (AIRC), the Italian Space Agency and by the Fondazione ONLUS-Buzzi.
References (112)
Mechanisms leading to chromosomal instability
Semin. Cancer Biol.
(2005)Biomarkers in environmental carcinogenesis research: striving for a new momentum
Toxicol. Lett.
(2006)- et al.
Number of centromeric signals in micronuclei and mechanisms of aneuploidy
Toxicol. Lett.
(2006) Molecular epidemiology in cancer research
Mol. Aspects Med.
(1998)Cytogenetic biomarkers and genetic polymorphisms
Toxicol. Lett.
(2004)- et al.
Chromosomal aberrations and SCEs as biomarkers of cancer risk
Mutat. Res.
(2006) Cytokinesis-block micronucleus assay evolves into a “cytome” assay of chromosomal instability, mitotic dysfunction and cell death
Mutat. Res.
(2006)- et al.
Methodological issues in pooled analysis of biomarker studies
Mutat. Res.
(2002) The in vitro micronucleus technique
Mutat. Res.
(2000)- et al.
Radiosensitivity of blood lymphocytes from basocellular carcinoma patients, as detected by the micronucleus assay
Mutat. Res.
(1996)